Catalog No.
RHC00802
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
Cold-insoluble globulin, CIG, FN, Fibronectin, FN1, EDB, EDB-FN
Concentration
1.61 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P02751
Applications
Blocking, ELISA, IHC, IF, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1375
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors., PMID:40447351
Development and validation of a quantitative Orthopoxvirus immunoassay to evaluate and differentiate serological responses to Mpox infection and vaccination., PMID:39987746
Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers., PMID:39774967
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice., PMID:39773310
MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer., PMID:39211789
IL-1β Inhibition Partially Negates the Beneficial Effects of Diet-Induced Atherosclerosis Regression in Mice., PMID:38695167
Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening., PMID:38033116
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial., PMID:37922632
Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time., PMID:37919289
CAR-T Therapy Targets Extra Domain B of Fibronectin Positive Solid Tumor Cells., PMID:37815216
Temporal transformer-spatial graph convolutional network: an intelligent classification model for anti N-methyl-D-aspartate receptor encephalitis based on electroencephalogram signal., PMID:37700752
A serologically assessed neo-epitope biomarker of cellular fibronectin degradation is related to pulmonary fibrosis., PMID:37343745
Clinical Characteristics and Outcomes Among Travelers With Severe Dengue : A GeoSentinel Analysis., PMID:37335991
Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies., PMID:37167766
Bioanalysis of an antibody drug conjugate (ADC) PYX-201 in human plasma using a hybrid immunoaffinity LC-MS/MS approach., PMID:37094503
An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties., PMID:36839699
Intratumoral nanobody-IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice., PMID:36712341
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)., PMID:36314242
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial., PMID:36192552
CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B., PMID:36139437
Evaluation of EDB Fibronectin in Plasma, Patient-Derived Xenograft Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tumor Tissues Using Immunoaffinity LC-MS/MS., PMID:36049057
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity., PMID:36038263
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade., PMID:35793468
ED-B-Containing Isoform of Fibronectin in Tumor Microenvironment of Thymomas: A Target for a Theragnostic Approach., PMID:35681572
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo., PMID:35139908
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis., PMID:34610987
Understanding Seizures and Prognosis of the Extreme Delta Brush Pattern in Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis: A Systematic Review., PMID:34589370
An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease., PMID:34576184
LRG1 Expression Is Elevated in the Eyes of Patients with Neovascular Age-Related Macular Degeneration., PMID:34445590
Targeting the tumor microenvironment with amphiphilic near-infrared cyanine nanoparticles for potentiated photothermal immunotherapy., PMID:34147723
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas., PMID:33901793
Using EEG and MEG to characterize extreme delta brush in a patient with anti-NMDA receptor encephalitis., PMID:33752613
Immunotherapy with Immunocytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX., PMID:33443104
Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors., PMID:33216834
A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo., PMID:33110477
Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin., PMID:33042274
Etoposide and immunotherapy can improve the outcome of severe anti-GABAB R encephalitis presenting with delta brush: A case report., PMID:32925748
Human fibronectin extra domain B as a biomarker for targeted therapy in cancer., PMID:32386436
FluoroCalins: engineered lipocalins with novel binding functions fused to a fluorescent protein for applications in biomolecular imaging and detection., PMID:31927584
Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade., PMID:31803362
Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice., PMID:31790729
Early Multidisciplinary Intensive-care Therapy can Improve Outcome of Severe Anti-NMDA-receptor Encephalitis Presenting with Extreme Delta Brush., PMID:31637048
Activation of αvβ3 Integrin Alters Fibronectin Fibril Formation in Human Trabecular Meshwork Cells in a ROCK-Independent Manner., PMID:31529121
Rational Design of Nanocarriers for Intracellular Protein Delivery., PMID:31496027
Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery., PMID:31374479
The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors., PMID:31374124
Mitochondria-Targeting, Intracellular Delivery of Native Proteins Using Biodegradable Silica Nanoparticles., PMID:30994955
Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients., PMID:30871800
A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy., PMID:30600870
Antibody-Assisted Delivery of a Peptide-Drug Conjugate for Targeted Cancer Therapy., PMID:30521347
For research use only. Not for human or drug use.
